Isotechnika Receives Notice of Allowance for mTOR Inhibitor, TAFA93

Edmonton, Alberta, November 21 (ots/PRNewswire) - Isotechnika Inc.
(TSX: ISA) today announced the Company has received a Notice of
Allowance from the United States Patent and Trademark Office based
on U.S. Patent Application Serial No. 10/845,747 for TAFA93,
including both composition of matter and methods of use claims. This
is the first patent to be issued in the United States for this
technology. Furthermore, patents are pending in 15 additional
countries relating to TAFA93, the Company's second immunosuppressive
drug.

TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR
inhibitor, which is a class of drugs currently used in combination
with calcineurin inhibitors to prevent organ rejection following
transplantation. This class of drugs, in addition to transplantation,
has potential for use in stent technology, autoimmune disease and
oncology. On September 30, 2005, Isotechnika entered into an
exclusive worldwide licensing agreement with Atrium Medical
Corporation ("Atrium") for the use of ISA247 and TAFA93 specifically
with drug eluting devices for the non-systemic treatment of vascular,
cardiovascular, target vessel and tissue disorders.

The successful completion of the Phase 1 TAFA93 trials, announced
earlier this year, has fulfilled one of the Company's commitments to
Atrium and allows them to continue moving forward with their drug
eluting stent technology program.

"This Notice of Allowance allows us to build our immunosuppressive
patent portfolio to include TAFA93," said Dr. Randall Yatscoff,
Isotechnika's President & CEO. "We look forward to receiving
additional patent protection for this novel technology."

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed a
Canadian Phase III human clinical trial for the treatment of moderate
to severe psoriasis. ISA247 is currently being investigated in a
North American Phase IIb human clinical trial for the prevention of
kidney graft rejection. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93 which
successfully completed Phase I clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.

Partnerships

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non-systemic treatment of vascular, cardiovascular, target vessel
and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-780-487-1600 Ext.246, Fax:
+1-780-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-780-909-4661, Fax: +1-780-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com